July 30 (Reuters) - Stryker Corp ( SYK ) posted an

upbeat second-quarter profit on Tuesday, as demand for its

medical and surgical devices rose, driven by growth in

non-urgent surgeries.

On an adjusted basis, the company reported a profit of $2.81

per share for the quarter ended June 30, slightly above

analysts' estimates of $2.79 per share.

The joint-implant maker also raised its annual profit per

share guidance to betweeen $11.9 and $12.1 from previous range

of $11.85 to $12.05. The average Wall Street estimate for 2024

profit is $11.95 per share, according to LSEG data.

Demand for medical implant devices has surged since last

November, as more people have opted for surgical treatments that

were deferred during the pandemic, leading to an increase in

procedural volumes.

Sales at Stryker's medical surgery and neurotechnology unit

rose 9% to $3.1 billion, while sales in the orthopedics and

spine segment rose 7.9% to $2.3 billion.

The Michigan-based company, which offers implants for joint

replacement, trauma and spine-based surgeries, surgical

equipment, among other products, now expects 2024 organic net

sales growth to be in the range of 9% to 10%, higher than its

previous forecast of 8.5% to 9.5%.

The company reported a 8.5% rise in quarterly revenue to

$5.4 billion, in line with LSEG estimates of $5.41 billion.